Mahamaya Lifesciences Ltd Q4 FY26 results press release summary

Results press release of 26 May 2026, summarised by AI from the filing.

Mahamaya Lifesciences FY26 revenue ₹32,887.30 lakhs, up 24.50%, with EBITDA ₹3,425.88 lakhs and PAT ₹1,652.33 lakhs.

Key takeaways

1. FY26 revenue Revenue from operations ₹32,887.30 lakhs (FY25: ₹26,414.86 lakhs, +24.50%).
2. FY26 EBITDA EBITDA ₹3,425.88 lakhs (FY25: ₹2,583.29 lakhs, +32.06%); margin 10.42% (FY25: 9.82%, +60 bps).
3. FY26 PAT PAT ₹1,652.33 lakhs (FY25: ₹1,281.16 lakhs, +28.97%); margin 5.02% (FY25: 4.85%, +17 bps).
4. H2 FY26 H2 FY26 revenue from operations ₹16,580.93 lakhs and EBITDA ₹21,789.84 lakhs, with EBITDA margin 10.79%.
5. Adjustments FY26 profitability impacted by accounting and listing-related adjustments of approximately ₹411 lakhs.

Original filing on BSE

Mahamaya Lifesciences Ltd earnings call, investor presentation and press release summaries

• Q4 FY26: Results press release (26 May 2026)
• Other events: Investor presentation (7 Aug 2026)